Casper Marc N's Form 4 filing
Thermo Fisher Scientific Inc. (TMO) · filed Nov 4, 2022
- Accession no.
- 0001127602-22-024971
- Filed
- Nov 4, 2022
- Trade date
- Nov 3, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 8 non-derivative transactions. Open-market sales total $4.00M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Casper Marc NCIK 0001216055 | Director, Officer (Chairman & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 3, 2022 | Common Stock | SSaleDisposed | −800 | $483.13F2 | −$386,504 | 185,404.53 | Direct | |
| Nov 3, 2022 | Common Stock | SSaleDisposed | −332 | $483.99F3 | −$160,684.68 | 185,072.53 | Direct | |
| Nov 3, 2022 | Common Stock | SSaleDisposed | −200 | $485.46F4 | −$97,092 | 184,872.53 | Direct | |
| Nov 3, 2022 | Common Stock | SSaleDisposed | −1,976 | $486.82F5 | −$961,956.32 | 182,896.53 | Direct | |
| Nov 3, 2022 | Common Stock | SSaleDisposed | −2,160 | $487.85F6 | −$1,053,756 | 180,736.53 | Direct | |
| Nov 3, 2022 | Common Stock | SSaleDisposed | −1,632 | $488.97F7 | −$797,999.04 | 179,104.53 | Direct | |
| Nov 3, 2022 | Common Stock | SSaleDisposed | −1,000 | $489.99F8 | −$489,990 | 178,104.53 | Direct | |
| Nov 3, 2022 | Common Stock | SSaleDisposed | −100 | $490.74 | −$49,074 | 178,004.53 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $482.52 to $483.48, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), and (8) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.64 to $484.44, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.25 to $485.66, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.41 to $487.35, inclusive.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.42 to $488.32, inclusive.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $488.49 to $489.40, inclusive.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $489.59 to $490.49, inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
One of two Form 4's filed on November 4, 2022 for the reporting of transactions occurring on November 2, 2022 and November 3, 2022, both partially included in the first Form 4. The second Form 4 includes additional transactions occurring on November 3, 2022 that could not be included in the first Form 4 due to a limitation on the number of line items that can be included per table in a single Form 4.